Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyruvate kinase isoenzyme R (PK-R) is the erythrocyte-specific isoform of the enzyme pyruvate kinase, encoded by the PKLR gene. It catalyzes the final, irreversible step of glycolysis: the transfer of a phosphate group from phosphoenolpyruvate (PEP) to ADP, forming ATP and pyruvate. In mature red blood cells, which lack mitochondria, PK-R is essential for ATP generation and cell survival. PK-R operates as a homotetramer and is allosterically activated by fructose 1,6-bisphosphate; its activity is subject to regulation by other effectors such as ATP. Mutations in PKLR can cause pyruvate kinase deficiency, leading to nonspherocytic hemolytic anemia, a common hereditary red blood cell disorder. Pharmacological activators, such as mitapivat, aim to restore enzymatic function in affected patients. PK-R function and deficiency are key biomarkers in clinical settings[1][2][4][5][6].
Allosteric activation of PK-R to enhance enzyme activity, increase ATP production, and improve erythrocyte survival
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyruvate kinase isoenzyme R (human erythrocyte) (PK-R).